Harnessing data to improve patient access and optimize gross-to-net

Discover the data and metrics you should be tracking to evaluate patient access.  

Feb. 27, 2023

Medicare maintains limits on Eisai’s new Alzheimer’s drug

Eisai and Biogen have data showing Leqembi slows cognitive decline, but CMS won’t budge until FDA converts its approval from accelerated to full.

By Jonathan Gardner • Feb. 23, 2023

Explore the Trendline➔

Drug pricing

President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.

By BioPharma Dive staff

Medicaid, with planned payment pilot, girds for influx of pricey gene therapies

The proposed model could help state Medicaid agencies explore different kinds of outcomes-based payment schemes, but may come too late to prepare for the first sickle cell gene therapy.

By Ned Pagliarulo • Feb. 21, 2023

Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’

Many top-selling products will lose patent protection by the end of the decade, putting pressure on companies to replace lost revenue with new medicines.

By Jonathan Gardner • Feb. 21, 2023

CMS plans trio of experiments aimed at lowering drug costs

The pilot programs could allow adjusted payments for drugs cleared under accelerated approval and help states manage the costs of gene therapies.

By Christopher Newman • Feb. 15, 2023

Medicare to collect drug price rebates starting in 2025

CMS laid out how it plans to implement a key provision of the Inflation Reduction Act, which requires drugmakers to pay rebates on price hikes within Medicare that are greater than inflation.

By Christopher Newman • Feb. 10, 2023

In address to Congress, Biden touts drug pricing law and pushes insulin cost caps

In his State of the Union speech, Biden threatened to veto any efforts to repeal the legislation and chastised drugmakers for the high cost of insulin.

By Kristin Jensen • Feb. 8, 2023

Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug

The world’s best-selling drug will face pricing pressure as rivals try to steal share from AbbVie’s $20 billion-a-year flagship product in the U.S. 

By Jonathan Gardner • Jan. 31, 2023

Moderna draws more lawmaker criticism for COVID vaccine pricing plan

Senators Warren and Welch urged the biotech to reconsider a planned price hike to between $110 and $130 a dose, and sought answers to a long list of questions.

By Kristin Jensen • Jan. 26, 2023

Pfizer expands not-for-profit pledge to include more medicines

The pharma is now committing to providing all of the roughly 500 products in its portfolio, including antibiotics and cancer drugs, to 45 lower-income countries.

By Kristin Jensen • Jan. 17, 2023

California files suit against PBMs over insulin prices

The state filed suit Thursday against pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, alleging they worked with drugmakers to drive up the price of insulin.

By Hailey Mensik • Jan. 13, 2023

HHS lays out timing for drug price negotiations

The agency will begin discussions on how it will negotiate Medicare drug prices in the spring and publish a list of the first 10 drugs selected by Sept. 1, 2023.

By Christopher Newman • Jan. 11, 2023

Sanders to target healthcare costs as leader of influential Senate committee

The longtime congressman and “Medicare for All” proponent will soon assume leadership of the Senate HELP committee, giving him sway in one of the nation’s most broadly influential health policy forums.

By Sydney Halleman • Jan. 9, 2023

Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

The pharma set the average annual cost of it and Biogen’s newly approved medicine Leqembi to $26,500, below the cost of the companies’ earlier drug Aduhelm but above one estimate of cost effectiveness.

By Ned Pagliarulo • Jan. 6, 2023

Pharma companies boost drug prices to start year, but hikes lag inflation

Analysts noted hundreds of list price increases, including dozens by Pfizer. Many checked in around 5%, roughly in line with hikes taken in recent years.

By Jonathan Gardner • Jan. 3, 2023

Gene therapy approval won, Bluebird takes on next challenge: selling it

The biotech is still waiting to treat its first commercial patient with Zynteglo, but says it has not seen insurers deny coverage for the beta thalassemia drug.

By Ned Pagliarulo • Dec. 12, 2022

Life science investment outlook: thinking beyond the pandemic

Learn about the investment landscape for life science companies, heading into 2023.

Dec. 12, 2022

Sanders poised to lead Senate health committee

The longtime pharma critic is set to become chair of the HELP Committee, a post that holds significant power in directing congressional efforts on healthcare issues.

By Susan Kelly • Nov. 28, 2022

FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar

Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.

By Christopher Newman • Nov. 18, 2022

Divided Congress after midterms will allow HHS to execute on policy priorities, Becerra says

The agency is focused on implementing drug price negotiation in Medicare and surprise billing regulations, according to the secretary.

By Rebecca Pifer • Nov. 16, 2022

EQRx redraws ‘radical’ drug pricing plans for first two drugs

The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.

By Jonathan Gardner • Nov. 10, 2022

Pharma earnings outline drug law’s looming impact on sales, development

While companies remain unsure of the Inflation Reduction Act's effects, some began to warn investors about the likelihood of lower sales and reduced profits.

By Christopher Newman • Nov. 9, 2022

Inflation Reduction Act: What are the healthcare implications?

The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.

Oct. 31, 2022

Worried about provider consolidation? Learn about GoodRx engagement solutions

GoodRx has developed strong relationships with both patients and providers over the past decade and is helping pharmaceutical manufacturers address the changes resulting from this trend.

Oct. 10, 2022

Amylyx sets ALS drug price at $158,000 per year, opening new debate on cost

The list price is slightly lower than another ALS therapy approved five years ago, but well above what one drug cost watchdog believes to be reasonable, given its purported benefit.

By Jacob Bell • Sept. 30, 2022